Akebia Therapeutics appoints Erik Ostrowski as CFO and Chief Business Officer

Akebia Therapeutics, Inc.

Erik Ostrowski appointed Senior VP, CFO, Chief Business Officer and Treasurer, effective June 24, 2024.
Base salary of $540,000, annual bonus target up to 45% of base salary.
Granted options to purchase 500,000 shares (4-year vest) and 350,000 RSUs (3-year vest).
Ostrowski previously served as President/Interim CEO and CFO of AVROBIO, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-06-24
Filed: June 24, 2024, 7:59 PM ET

On June 24, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Erik Ostrowski as the Company’s Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Ostrowski was appointed as Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer at Akebia Therapeutics, Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer

Exact text from the filing

On June 24, 2024, Akebia Therapeutics, Inc. (the “Company”) announced the appointment of Erik Ostrowski as the Company’s Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-24-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.